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Objective: There is an increased risk of developing knee osteoarthritis (OA) following anterior cruciate
ligament (ACL) injury. Biomarkers may provide diagnostic, prognostic, or burden of disease indicators of
OA before radiographic changes become apparent. Unfortunately, there has been no systematic review to
clarify which biomarkers may be most informative following injury. Therefore, this review critically
investigated existing studies of OA-related biomarkers in ACL-deﬁcient (ACL-D) and reconstructed (ACL-
R) patients to summarize the current evidence and identify knowledge gaps.
Design: A systematic review of the literature in Web of Science and PubMed databases (1960eJune 2014)
was performed. All English-language caseecontrol and longitudinal studies assessing OA-related bio-
markers in ACL-D and ACL-R patients were considered. Data regarding biomarker changes over time
within ACL-D and ACL-R patients as well as differences in ACL-D/ACL-R patients compared with a control
group were extracted from pertinent studies.
Results: A descriptive summary of 20 included studies was produced. In ACL-D patients compared with
controls, synovial ﬂuid biomarkers indicated elevated collagen turnover, while the inﬂammatory cyto-
kine response was inconclusive. In ACL-R patients, serum concentrations indicated decreased collagen
breakdown, but urine concentrations were indicative of greater collagen breakdown when compared to
controls. Compared to preoperative values, the overall inﬂammatory cytokine response measured with
synovial ﬂuid biomarkers increased while plasma biomarkers did not change following reconstruction.
Conclusion: Patients with ACL-D or ACL-R have altered biomarkers indicative of OA. More research with
standardized reporting is needed to effectively determine which biomarkers are the most indicative for
OA development and progression following ACL injury.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.M.S. Harkey, Department of
ina at Chapel Hill, 209 Fetzer
bluc@live.unc.edu (B.A. Luc),
cc.edu (A.C. Thomas), jeffrey.
.C. Hackney), brian@unc.edu
ternational. Published by Elsevier LIntroduction
Anterior cruciate ligament (ACL) injury is one of the most
common traumatic knee injuries sustained by relatively young and
physically active individuals, with an estimated 250,0001 ACL in-
juries and 175,0002 ACL reconstructions occurring annually in the
United States. People with a history of knee injury have between
286%3 and 495%4 greater odds of developing knee osteoarthritis
(OA) than thosewho have never sustained a knee injury. It has been
hypothesized that an underlying cascade of structural and
biochemical changes occurs early following ACL injury, ultimately
resulting in the onset of knee OA. In fact, one-third of patientstd. All rights reserved.
Table I
Biomarker abbreviations
BMP Bone morphogenic protein
BSP Bone sialoprotein
C12C Collagen type I and II cleavage product
C2C Collage type II cleavage product
COMP Cartilage oligomeric matrix protein
CTX-II C-terminal cross-linked telopeptide of type II collagen
CPII Procollagen II C-propeptide
CRP C-reactive protein
CS846 Aggrecan Chondroitin Sulfate 846 epitope
GM-CSF Granulocyte-macrophage colony-stimulating factor
HA Hyaluronic acid
IFN-g Interferon-gamma
IL Interleukin
IL-1ra Interleukin-1 receptor antagonist
MCP-1 Monocyte chemotactic protein-1
MIP-1b Macrophage inﬂammatory protein-1 beta
MMP Matrix metalloproteinase
NO Nitric Oxide
OPN Osteopontin
PDGF Platelet-derived growth factor
TIMP Tissue inhibitor of metalloproteinase
TGF-b Transforming growth factor-beta
TNF-a Tumor necrosis factor-alpha
VEGF Vascular endothelial growth factor
WF6 Chondroitin sulfate epitope
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decade following injury regardless of surgical reconstruction sta-
tus5. Although rapidly progressive knee OA occurs in themajority of
ACL injured patients within two decades of injury5, there is no
effective treatment to prevent the development of OA following
ACL injury. One key reason for a lack of preventive therapies may be
the lack of validated methods to diagnose and monitor early dis-
ease6. With an estimated $3 billion spent annually on the treatment
of posttraumatic OA7, it is critical that methods be developed to
evaluate the presence and progression of early-stage OA following
ACL injury or ACL reconstruction (ACL-R).
Understanding factors that lead to the development of post-
traumatic OA following ACL injury and ACL-R is important for
decreasing the need of future total knee arthroplasty as well as
limiting the extent of chronic disability and mitigating the risk of
developing inactivity related co-morbid health conditions (e.g.,
obesity, type II diabetes, cardiovascular disease)8,9. Currently,
posttraumatic knee OA is commonly diagnosed based on the
presence of radiographic signs of the disease and complaints of
knee pain10. However, radiographic assessments of OA rely on the
presence of joint space narrowing and osteophyte formation that
are signs of late-stage joint degradation has occurred, but the
development of OA possibly originates early following traumatic
injury due to a cascade of biochemical and biomechanical events.
The evaluation of biochemical markers (biomarkers) that indicate
abnormal joint turnover shortly after injurymay be an important tool
in understanding and treating posttraumatic knee OA11. Biomarker
evaluation may provide an effective approach for detecting OA
development before signiﬁcant advancement of the disease. How-
ever, a wide range of possible biomarkers has been used to detect
early changes in tissue turnover following ACL injury and no
consensus on their validity has been reached. This review seeks to
systematicallyevaluate and synthesize studieswith caseecontrol and
repeated measures designs that evaluate biomarkers related to joint
metabolismand joint inﬂammation inbothACLdeﬁcient (ACL-D) and
ACL-R patients compared with healthy, matched controls as well as
evaluating changes in biomarkers over multiple time intervals. The
goals of this revieware to highlight the current evidenceof biomarker
alterations following ACL injury, and to identify potential gaps in the
literature to aid in the development of future studies.
Methods
Search strategy
The Preferred Reporting Items for Systematic Review and Meta-
Analyses (PRISMA) guidelines12 and a written protocol were fol-
lowed to conduct an exhaustive systematic, electronic search of the
Web of Science and PubMed databases. A reference librarian at the
University of North Carolina at Chapel Hill assisted the investigators
in performing the search. The following search was performed
initially performed on August 12, 2013 and updated on June 9,
2014: ACL AND (blood OR urine OR synovial ﬂuid OR serum OR
plasma OR biomarkers). We included studies published since
January 1, 1960 that were written in English and used human par-
ticipants. Bibliographies from all relevant studies found in the
initial online search were cross-referenced to identify any other
pertinent articles. The deﬁnitions for biomarker abbreviations that
were used in the individual studies have been included in Table I.
Selection criteria
Our focus was on articles that evaluated wet, or ﬂuid based,
biomarkers related to the development of OA (joint metabolism
and inﬂammation) in human ACL-D and ACL-R patients. Threereviewers (MSH, BAL, BP) identiﬁed eligible articles if an article
met the following criteria: (1) enrolled ACL-D or ACL-R patients;
(2) included a control group or multiple time points for between
or within group comparisons; and (3) evaluated biomarker
change following ACL injury or ACL-R. An article was excluded if:
(1) treatment was used speciﬁcally in an attempt to alter
biomarker concentrations other than standard physical rehabili-
tation; (2) patients had a revision of previous ACL-R; or (3)
contralateral knee biomarker concentrations were used as control
group due to concerns about systemic alterations in biomarker
concentrations following injury, as well as potential aberrant gait
kinematics of the contralateral knee affecting biomarker
concentrations.Methodological quality assessment
The Critical Appraisal Skills Programme (CASP)13 was used to
evaluate the literature for: (1) clarity and preciseness of overall re-
sults of the study; (2) the validity of the results of the study; and (3)
relevance of the results of the study. The CASP score for case control
studies ranges from 0 to 11 points (11 ¼ highest quality), and the
CASP score for longitudinal studies ranges from 0 to 12 possible
points (12 ¼ highest quality; Tables II and III). Three authors (MSH,
BAL, BP) independently rated each included article and awarded a
total point value to each study. If there was a discrepancy between
the points awarded, the three authors discussed differences and
achieved a unanimous consensus regarding study inclusion.Data extraction
A standardized data extraction form was created by MSH and
reviewed and edited by BP. Two investigators (MSH and BAL)
extracted the type of biomarker (e.g., collagen breakdown, collagen
synthesis, pro-inﬂammatory cytokine), biomarker names, publica-
tion year, ACL status (deﬁcient or reconstructed), age and sex of
patients and controls, time since injury, time between injury and
surgery, concomitant knee injury, ﬂuid sample (e.g., synovial ﬂuid,
blood), assay analysis technique, and mean/median and standard
deviation/quartile values for biomarker levels by patient and con-
trol group.
Table II
ACL-D demographics and methodological quality
Author year Study
designz
ACL patients Includedx Control participants CASP score@
Age (years)* Biomarker time
points (weeks)*,y
N %F OA MCL LCL PCL MI Age (years)* N %F
Cameron 199714 CC 30.8(14e57) (0e0.14) 60 33% NR NR NR 34.2(16e52) 10 60% 5(11) 3,4,6,8,11,14
32(23e57) (0.14e3) 18 44% No No No
26.9(14e41) (12e728) 8 13% No No No
Chockalingam 201315 CC 29(14e53) (0e2) 57 36% No NR Yes 28(17e42) 8 25% 6(11) 3,4,8,10,11
(3e12)
(13e52)
(52þ)
Cuellar 201016 CC 33[3] 3.1(1.9e5.6) 12 25% NR No No 43(3) 15 47% 6(11) 3,6,7,10,11
Dahlberg 199417 CC 24(19:30) 0.7(0.3:1.1) 77 NR No Yes Yes 28(25:34) 10 NR 6(11) 3,6,7,8,11
97(80:146)
198(135:248)
230(180:293)
Higuchi 200618 CC 26.5(17e42) 32(2e140) 32 38% Yes No Yes 24.3(15e37) 6 17% 6(11) 6,7,8,10,11
Lohmander 199319 CC 28/24[10] 106/23[196] 207 44% No Yes Yes 29/28[7] 10 30% 4(11) 3,4,6,7,8,10,11
Lohmander 1994a23 CC 28/25[10] 103/22[184] 270 32% No Yes Yes 30/28[9] 6 0% 4(11) 3,4,6,7,8,10,11
Lohmander 1994b21 CC 25/22[10] 0.3/0.3[0.1] 24 46% No Yes Yes 29/28[7] 10 30% 4(11) 3,4,6,7,8,10,11
26/22[11] 0.7/0.7[0.1] 20 30% No
26/22[9] 1.2/1.1[0.2] 25 40% No
19/19[3] 2.7/2.1[0.2] 21 43% No
28/23[6] 20/22[7.3] 20 35% No
25/23[6] 48/48[11] 21 52% No
28/26[8] 89/88[9] 20 35% No
29/28[10] 132/128[16] 19 26% No
32/30[9] 256/262[68] 19 16% No
42/43[11] 625/523[279] 18 6% No
Lohmander 1996a22 CC 32(14e67) 105(0e1250) 114 30% No Yes Yes 29(17e43) 19 26% 4(11) 3,4,6,7,8,10,11
Lohmander 1996b24 CC 26(16e42) 28(0e1250) 156 28% NR NR Yes 28(20e40) 23 13% 4(11) 3,4,6,7,8,10,11
Lohmander 199920 CC 24(14e65) 4(0e1200) 159 30% NR Yes Yes 27(17e42) 9 11% 5(11) 3,4,6,8,10,11
Pruksakorn 200925 CC 31.6(18.4e42.8) 48(8e528) 33 12% No No Yes 32(18.0e44.5) 74 35% 9(11) 6,11
CASP Score@ ¼ Critical Appraisal Skills Programme: score obtained (maximum score), Bold ¼ Caseecontrol speciﬁc, Italics ¼ Longitudinal Speciﬁc.
1 Does not address clearly focused issue; 2 Does not use appropriate method to answer question; 3 Exposure not accurately measured to minimize bias; 4 Confounding factors
not accounted for; 5 Results are not precise; 6 Results are not believable; 7 Results cannot be applied to local population; 8 Results do not ﬁt with other available evidence; 9
Analysis not appropriate for design; 10 Cases not recruited in acceptable way; 11 Controls not selected in acceptable way; 12 Cohort not recruited in acceptable way; 13
Outcome not accurately measured to minimize bias; 14 Confounding factors not identiﬁed; 15 Follow up not complete enough.
* Mean/median, (range/25%:75%), [SD/SEM].
y 0 ¼ time of surgery, (þ) ¼ weeks post, () ¼ weeks pre.
z CC ¼ caseecontrol, CS ¼ cross-sectional, L ¼ Longitudinal.
x Participants were included with OA ¼ radiographic osteoarthritis, MCL/LCL/PCL ¼ concomitant injury to medial collateral, lateral collateral, and posterior cruciate liga-
ment, MI ¼ meniscus injury, NR ¼ not reported.
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The majority of studies did not present data in tabular form, and
we were unable to conduct any quantitative analysis of the results.
Corresponding authors were contacted by email for missing data,
but no additional results were obtained. Therefore, we have orga-
nized the results from each study into Tables VI and VII. These ta-
bles indicate the weeks from injury or surgery and whether the
biomarker concentrations were deemed either signiﬁcantly greater,
signiﬁcantly less, or unchanged when compared to either control
participants or a baseline measure (P < 0.05). We stratiﬁed the
results section by ACL status (ACL-D or ACL-R), type of biomarker
(joint metabolism [collagen, proteoglycan, or bone] or inﬂamma-
tory cytokines), and time from injury/surgery (<2 months, 2
monthse1 year, >1 year).
Results
Included study demographics and methodological quality
The initial online search identiﬁed 777 potential studies (Fig. 1).
Twenty studies met the speciﬁed inclusion criteria. Twelve14e25
studies assessed biomarker concentrations in ACL-D patients,
while eight studies26e33 assessed biomarker concentrations in
ACL-R patients (Fig. 1). All studies assessing ACL-D patients utilized
a caseecontrol study design. Among studies with ACL-R patients,ﬁve studies26,28,29,32,33 utilized a longitudinal design, two
studies27,31 utilized a caseecontrol design, and one study30 utilized
both a longitudinal and caseecontrol design. The mean CASP score
was 5.9 out of a possible 11 points for caseecontrol studies
(mode ¼ 6, range ¼ 4e9) and seven out of a possible 12 points for
longitudinal studies (mode ¼ 7, range ¼ 5e8). The most frequently
missed CASP item (95% of included studies) was that results could
not be applied to the local population; due to wide ranges of in-
clusion criteria, participant demographics, and follow-up times that
made it difﬁcult to compare results between studies and determine
the relevance of the study results (Tables II and III).
A total of 1701 patients (31% Female) [ACL-D: n ¼ 1410, 31%
Female; ACL-R: n ¼ 291, 30% Female] between the ages of 19 and
43 years were included. One study17 did not report the percentage
of female patients. A control group was included in 75% of the
studies14e25,27,30,31, with a total of 305 (28% Female) control par-
ticipants included [ACL-D: n ¼ 200, 28% Female; ACL-R: n ¼ 105,
30% Female] (Tables II and III). In the studies assessing ACL-D
patients, 11 studies14e24 collected synovial ﬂuid while only one
study25 collected serum (Table IV). In the studies assessing ACL-R
patients, four studies26,28,32,33 collected synovial ﬂuid, two
studies27,31 collected urine, two studies30,31 collected serum, and
one study29 collected plasma (Table V). Five studies27e29,31,33
assessing ACL-R patients reported graft type used during surgi-
cal reconstruction [patellar tendon: 50%; hamstring tendon: 34%;
allograft: 16%].
Table III
ACL-R demographics and methodological quality
Author year Study
designy
ACL patients Includedx Control participants CASP score@
Age (years)* Time
(injury-surgery)
(weeks)*
Biomarker time
points following
surgery (weeks)*,z
N %Female Graft typek OA MCL
LCL
PCL
MI Age
(years)*
N %Female
Akesen 200926 L 27(17e40) 84(4e284)[40] 0 16 6% NR NR NR NR NA 5(12) 4,6,7,8,
12,13,140.11(0.07e0.21)
Chmielewski
201227
CC 19.6[4.5] 9.9[9.1] 4 28 50% 16 HS, 1 PT,
11 AG
NR No Yes 19.9 [4.3] 28 50% 9(11) 4,8
8
12
16
Hayward 201128 L 28(17e45) (16e88) 0 14 0% 14 HS No No Yes NA 7(12) 4,6,8,
13,140.006
0.036
Mendias 201329 L 28(16e50)[2.4] 6e8 1 18 33% 15 PT, 3 AG NR NR NR NA 8(12) 4,6,8,14
0.43
2
5
12
18
26
Svoboda 201330 CC L M ¼ 20.26(1.29) NR 88.7(53.9) 45 13% NR NR No No ±2 years
within age
of ACL-D
subject
45 13% 10(11) 8
F ¼ 19.33(1.03) 101.9(56.1)
Tourville 201331 CC 28.8 10.0(2.6e22.1) 68(48e100)[10.4] 35 51% 1 HS, 31 PT,
3 AG
No No Yes 26.8 32 56% 9(11) 8,14
184(128e244)[35.2]
Yamaga 201232 L 25(14e48) 51.6(2e1040) 0 122 34% NR NR NR No NA 7(12) 4,6,8,
13,14M ¼ (15e47)
F ¼ (14e48)
0.6
Zysk 200433 L HS ¼ 26[4]
PT ¼ 28[5]
3.4[1] 0 13 8% 6 HS, 7 PT No No No NA 8(12) 4,6,8,14
1.0
CASP Score@ ¼ Critical Appraisal Skills Programme: score obtained (maximum score), Bold ¼ Caseecontrol speciﬁc, Italics ¼ Longitudinal speciﬁc.
1 Does not address clearly focused issue; 2 Does not use appropriate method to answer question; 3 Exposure not accurately measured to minimize bias; 4 Confounding factors
not accounted for; 5 Results are not precise; 6 Results are not believable; 7 Results cannot be applied to local population; 8 Results do not ﬁt with other available evidence; 9
Analysis not appropriate for design; 10 Cases not recruited in acceptable way; 11 Controls not selected in acceptable way; 12 Cohort not recruited in acceptable way; 13
Outcome not accurately measured to minimize bias; 14 Confounding factors not identiﬁed; 15 Follow up not complete enough.
* Mean/median, (range/25%:75%), [SD/SEM].
y CC ¼ caseecontrol, CS ¼ cross-sectional, L ¼ Longitudinal.
z 0 ¼ time of surgery, (þ) ¼ weeks post, () ¼ weeks pre.
x Participants included with OA ¼ radiographic osteoarthritis, MCL/LCL/PCL ¼ concommitant injury to medial collateral, lateral collateral or posterior cruciate ligament,
MI ¼ meniscus injury, NR ¼ not reported.
k Graft type: NR ¼ not reported, HS ¼ hamstring tendon, PT ¼ patellar tendon, AG ¼ allograft.
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radiographic knee OA (three of 32 subjects had Grade I on Inter-
national Knee Documentation Committee (IKDC) cartilage lesion
scale), eight studies14,15,17,19,21e23,25 excluded patients with knee
OA, and three studies16,20,24 did not report the presence of OA
(Table II). Of the ACL-R studies, three studies28,31,33 excluded pa-
tients with knee OA, and ﬁve studies26,27,29,30,32 did not reportTable IV
ACL-D biomarker analysis and data presentation information
Author year Biomarkers Sample*
Cameron 199714 IL-1a, IL-1B, IL-1Ra, TNF-a, IL-6, IL-8, GM-CSF SF
Chockalingam 201315 Tenascin-C SF
Cuellar 201016 IFN-g, IL-1b, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10,
IL-12, IL-13, IL-17, TNF-a, MCP-1, MIP-1b
SF
Dahlberg 199417 Aggrecan fragments, MMP-3, TIMP-1 SF
Higuchi 200618 IL-1b, TNF-a, IL-6, MMP-3, TIMP-1 SF
Lohmander 199319 MMP-3, MMP-8, TIMP-1, proteoglycan fragments SF
Lohmander 1994a23 COMP SF
Lohmander 1994b21 MMP-3, TIMP-1, proteoglycan fragments SF
Lohmander 1996a22 Bone sialoprotein SF
Lohmander 1996b24 CPII SF
Lohmander 199920 Aggrecan epitope 846 SF
Pruksakorn 200925 Chondroitin sulfate epitope (WF6), HA S
* SF ¼ synovial ﬂuid, S ¼ serum.
y ELISA ¼ enzyme linked immunosorbent assay.
z SD ¼ standard deviation, SE ¼ standard error.presence of knee OA (Table III). Six17,19e23 of the ACL-D studies
included patients with concomitant injury of the medial collateral
ligament, lateral collateral ligament, or posterior cruciate ligament,
while four studies14,16,18,25 excluded patients with concomitant
ligament injury, and two studies15,24 did not report the presence of
ligament injury (Table II). Five27,28,30,31,33 of the ACL-R studies
excluded patients with concomitant ligament injury, while threeAssayy Data presentationz
Sandwich ELISA Figures: mean (SE)
ELISA Figures: median 10%, 25%, 75%, 90%
17-plex inﬂammatory cytokine panel Text: mean (SE)
Aggrecan ¼ Alcian blue precipitation
MMP-3/TIMP-1 ¼ sandwich immunoassay
Table: median (25%:75 %)
Sandwich ELISA Table: mean (SD)
Sandwich immunoassay Figures: mean (SE)
ELISA Figures: median 10%, 25%, 75%, 90%
ELISA sandwich immunoassay Figures: mean (SE)
Immunoassay Figures: median 10%, 25%, 75%, 90%
Enzyme immunoassay Figures: median 10%, 25%, 75%, 90%
Competitive immunoassay ELISA Text: median (range)
Competitive immunoassay ELISA Table: median (SE)
Table V
ACL-R biomarker analysis and data presentation information
Author year Biomarkers Sample* Assayy Data presentationz
Akesen 200926 MMP-8, TIMP-1, TNF-a SF Activity assay kit/immunoassay Text; mean(SD)
Chmielewski 201227 CTX-II U ELISA Figures: log mean (SD)
Hayward 201128 IFNg, IL-1b, IL-1ra, IL-2, IL-4, IL-6, IL-6R, TGF-b, TNF-a SF Multiplex assay Figures: box plot
Mendias 201329 TNF-a, IL-1a, IL-1b, IL-1ra, IL-6, IL-10, COMP, TGF-b, CRP P ELISA multiplex assay Figures: mean (SE)
Svoboda 201330 CPII, CS846, C12C, C2C S ELISA Table: median (IQR)
Tourville 201331 Ratios between uC2C, uCTX-II, uC1C2, sCPII U/S ELISA Table mean (SD) median (range)
Yamaga 201232 OPN SF ELISA Figures: mean (SE)
Zysk 200433 TNF-a, IL-1b, IL-6, BMP-2, NO SF Sandwich ELISA Text: mean (SE)
* SF ¼ synovial ﬂuid, S ¼ serum, U ¼ urine, P ¼ plasma, U/S ¼ ratio of urine to serum.
y ELISA ¼ enzyme linked immunosorbent assay.
z SD ¼ standard deviation, SE ¼ standard error, IQR ¼ interquartile range.
Table VI
Temporal alterations of biomarker concentrations in ACL-D patients
Type Biomarker Change in
biomarker
Sample* Timing of sample
acquisition for
comparison to initial
time point
Timing of sample acquisition for
comparison to control group
Weeks from injuryy Weeks from injuryy
Cartilage degradation Tenasin-C [ SF e 29(0e510)15
COMP [ SF e 103[184]23
Collagen synthesis CPII [ SF e 28(0e1250)24
Collagen degradation
enzymes
MMP-3 (STR) [ SF e 0.3[0.1]21, 0.7[0.1]21, 0.7(0.3:1.1)17, 1.2[0.2]21, 2.7[0.2]21,
20[7.3]21, 32(2e140)18, 48[11]21, 89[9]21, 97(80:146)17,
106[196]19, 132[16]21, 198(135:248)17, 230(180:293)17,
256[68]21, 625[279]21
MMP-1 (COL) [ SF e 106[196]19
TIMP-1 [ SF e 0.3[0.1]21, 0.7[0.1]21, 0.7(0.3:1.1)17, 1.2[0.2]21, 2.7[0.2]21,
20[7.3]21, 32(2e140)18, 48[11]21, 89[9]21, 97(80:146)17,
106[196]19, 132[16]21, 256[68]21, 625[279]21
¼ SF e 198(135:248)17, 230(180:293)17
Proteoglycan and
glycosaminoglycan
degradation
WF6-Epitope [ S e 48(8e528)25
HA ¼ S e 48(8e528)25
Proteoglycan
fragments
[ SF e 0.3[0.1]21, 0.7(0.3:1.1)17, 0.7[0.1]21, 1.2[0.2]21, 2.7[0.2]21,
20[7.3]21, 48[11]21, 89[9]21, 106[196]19, 132[16]21,
256[68]21, 625[279]21
¼ SF e 97(80:146)17, 198(135:248)17, 230(180:293)17
Proteoglycan synthesis Aggrecan 846
epitope
[ SF e 4(0e1200)20
Bone degradation BSP [ SF e 105(0e1250)22
Pro-inﬂammatory
cytokine
IL-1a ¼ SF e (0e0.14)14, (0.14e3)14, (12e728)14
IL-1b ¼ SF e (0e0.14)14, (0.14e3)14, 3.1(1.9e5.6)16, (12e728)14
IL-2 ¼ SF e 3.1(1.9e5.6)16
IL-5 ¼ SF e 3.1(1.9e5.6)16
IL-6 [ SF e (0e0.14)14, (0.14e3)14, 3.1(1.9e5.6)16, 32(2e140)18
¼ SF e (12e728)14
IL-8 [ SF e (0e0.14)14, (0.14e3)14
¼ SF e 3.1(1.9e5.6)16, (12e728)14
IL-17 ¼ SF e 3.1(1.9-5.6)16
TNF-a [ SF e (0e0.14)14, (0.14e3)14, (12e728)14, 32(2e140)18
¼ SF e 3.1(1.9e5.6)16
Anti-inﬂammatory
cytokine
IL-1ra [ SF e (0e0.14)14
Y SF e (0.14e3)14, (12e728)14
IL-4 ¼ SF e 3.1(1.9e5.6)16
IL-10 ¼ SF e 3.1(1.9e5.6)16
IL-12 ¼ SF e 3.1(1.9e5.6)16
IL-13 ¼ SF e 3.1(1.9e5.6)16
IFN-g [ SF e 3.1(1.9e5.6)16
Anabolic cytokines IL-7 ¼ SF e 3.1(1.9e5.6)16
G-CSF ¼ SF e 3.1(1.9e5.6)16
GM-CSF [ SF e (12e728)14
¼ SF e (0e0.14)14, (0.14e3)14, 3.1(1.9e5.6)16
Chemokines MIP-1b [ SF e 3.1(1.9e5.6)16
MCP-1 [ SF e 3.1(1.9e5.6)16
Y: Decrease in biomarker concentration.
[: Increase in biomarker concentration.
¼: No difference in biomarker concentration.
* SF ¼ synovial ﬂuid, S ¼ serum.
y Mean/median, (range/25%:75%), [SD/SEM].
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Table VII
Temporal alterations of biomarker concentrations in ACL-R patients
Type Biomarker Change in
biomarker
Sample* Timing of sample acquisition for
comparison to initial time point
Timing of sample acquisition for
comparison to control group
Weeks from surgeryy Weeks from surgeryy
Cartilage degradation COMP ¼ P 229, 529, 1229, 1829, 2629 e
Y P 0.4329 e
Collagen metabolismz C2C:CPII ¼ U/S e 68(48e100)[10.4]31, 184(128e244)[35.2]31
Y S e 101.9(56.1)30
CTX-II:CPII [ U/S e 68(48e100)[10.4]31, 184(128e244)[35.2]31
C12C:CPII [ U/S e 68(48e100)[10.4]31, 184(128e244)[35.2]31
Y S e 101.9(56.1)30
Collagen degradation CTX-II [ U e 427, 827, 1227, 1627
C12C Y S 101.9(56.1)30 101.9(56.1)30
C2C Y S 101.9(56.1)30 101.9(56.1)30
Collagen synthesis CPII Y S 101.9(56.1)30 e
¼ S e 101.9(56.1)30
Collagen degradation
enzyme
MMP-8 (COL) ¼ SF 0.11(0.07e0.21)26 e
TIMP-1 [ SF 0.11(0.07e0.21)26 e
Proteoglycan synthesis CS846 [ S e 101.9(56.1)30
¼ S 101.9(56.1)30 e
Bone degradation NO ¼ SF 133 e
Pro-inﬂammatory
cytokine
IL-1a ¼ P 0.4329, 229, 529, 1229, 1829, 2629 e
IL-1b [ SF 0.00628, 0.03628 e
¼ P 0.4329, 229, 529, 1229, 1829, 2629 e
SF 133 e
IL-2 [ SF 0.00628, 0.03628 e
CRP [ P 0.4329 e
¼ P 229, 529, 1229, 1829, 2629 e
IL-6 [ SF 0.00628, 0.03628, 133 e
¼ P 0.4329, 229, 529, 1229, 1829, 2629 e
OPN Full [ SF 0.632 e
OPN N-half [ SF 0.632 e
TNF-a ¼ P 0.4329, 229, 529, 1229, 1829, 2629 e
SF 0.11(0.07e0.21)26, 133 e
Y SF 0.00628, 0.03628 e
Anti-inﬂammatory
cytokine
IFN-g [ SF 0.00628, 0.03628 e
IL-10 ¼ P 0.4329, 229, 529, 1229, 1829, 2629 e
IL-1Ra [ SF 0.00628, 0.03628 e
¼ P 0.4329, 229, 529, 1229, 1829, 2629 e
Anabolic cytokines PDGF [ SF 0.00628, 0.03628 e
VEGF [ SF 0.00628, 0.03628 e
TGF-b [ P 229 e
SF 0.00628, 0.03628 e
¼ P 0.4329, 529, 1229, 1829, 2629 e
BMP-2 [ SF 133 e
[: Increase in biomarker concentration.
¼: No difference in biomarker concentration.
Y: Decrease in biomarker concentration.
* SF ¼ synovial ﬂuid, S ¼ serum, U ¼ urine, P ¼ plasma, U/S ¼ ratio of urine to serum.
y Mean/median, (range/25%:75%), [SD/SEM].
z Increase in ratio ¼ greater degradation to synthesis.
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(Table III). Ten15,17e25 of the ACL-D studies included patients with
meniscus injuries, while two studies14,16 excluded patients with
meniscus injury (Table II). Three27,28,31 ACL-R studies included pa-
tients with meniscal injuries, three studies30,32,33 excluded ACL-R
patients with meniscal injuries, and two studies26,29 did not
report meniscal status (Table III).Biomarker concentrations
ACL-D studies
Collagen, proteoglycan, and bone biomarkers (Table VI)Within 1 week following injury (two studies)
Within the ﬁrst week following ACL injury, patients had greater
synovial ﬂuid concentrations of proteoglycan fragments17,21,
MMP-317,21, and TIMP-117,21 when compared to control participants.Between 1 week e 2 months following injury (three studies)
Between 1 week and 2 months after an ACL injury, patients had
greater synovial ﬂuid concentrations of proteoglycan frag-
ments17,21, MMP-317,21, TIMP-117,21, and aggrecan epitope-84620
compared with control participants.Between 2 months e 1 year following injury (ﬁve studies)
Between 2 months and 1 year post ACL injury, patients had
greater synovial ﬂuid concentrations of CPII24, MMP-317,18,21, and
TIMP-117,18,21 as well as serum WF625 compared with controls
participants. However, during this time period serum HA concen-
trations25 did not differ from control participants.Greater than 1 year following injury (six studies)
After the ﬁrst year following injury, ACL-D patients had elevated
synovial ﬂuid concentrations of COMP23, BSP22, MMP-119, Tenascin-
C15, MMP-317,21, and TIMP-117,21 compared to control participants.
However, 2 years following injury, synovial ﬂuid concentrations of
proteoglycan fragments17 and TIMP-117 did not differ from controls.
Initial Search: 8/12/13 
Updated Search: 6/9/13 
PubMed 
Web of Science 
Bibliography search: n = 0 
Title/abstract review: n = 777 
Records excluded: n = 29 
• Animal samples used 
• Patients received experimental intervention 
• Injured group did not include ACL injury 
• Non-fluid sample
Full text review: n =  56  
Data extraction: n= 27 
Included in qualitative analysis: n = 20 
ACL-D    ACL-R 
Cameron 199714  Akesen 200926 
Chockalingam 201315  Chmielewski 201227 
Cuellar 201016   Hayward 201128 
Dahlberg 199417  Mendias 201329 
Higuchi 200618  Svoboda 201330 
Lohmander 199319  Tourville 201331 
Lohmander 1994a23  Yamaga 201232 
Lohmander 1994b21  Zysk 200433 
Lohmander 1996a22 
Lohmander 1996b24 
Lohmander 199920 
Pruksakorn 200925 
Records excluded: n = 7 
• Not compared to control or baseline 
biomarker concentration 
Records excluded: n = 721 
Fig. 1. Flow diagram of the study selection process.
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Within 1 week following ACL injury, patients had greater sy-
novial ﬂuid concentrations of IL-1ra14, IL-614, IL-814, and TNF-a14
when compared to control participants. However, within the ﬁrst
week, there were no differences between ACL-D and control
participant synovial ﬂuid concentrations of IL-1a14, IL-1b14, and
GM-CSF14.Between 1 week e 2 months following injury (two studies)
Between 1 week and 2 months following injury, ACL-D patients
had greater synovial ﬂuid concentrations of IL-616, MCP-116,
MIP-1b16, and IFN-g16. However, between the ﬁrst week and two
months following injury, there were no observed differences be-
tween ACL-D and control participant synovial ﬂuid concentrations
of IL-1b16, IL-216, IL-416, IL-516, IL-716, IL-816, IL-1016, IL-1216, IL-1316,
and IL-1716. There were heterogeneous ﬁndings for TNF-a between
the ﬁrst week and two months following injury, with one study14observing an increase, while another study16 found no change be-
tween ACL-D patients and control participants.
Between 2 months e 1 year following injury (two studies)
Between 2 months and 1 year following injury, ACL-D patients
presented with greater synovial ﬂuid concentrations of IL-614,18, IL-
814, and TNF-a14,18. No differences in synovial ﬂuid concentrations
of IL-1a14, IL-1b14, and GM-CSF14 were observed between ACL-D
patients and control participants at time points ranging from 2
months and 1 year following injury. During the 2 month to 1 year
time interval the ACL-D patients presented with lower synovial
ﬂuid concentrations of IL-1ra14 compared to control participants.
Greater than 1 year following injury (one study)
After the ﬁrst year following ACL injury, ACL-D patients had
greater synovial ﬂuid concentrations of TNF-a14 and GM-CSF14
compared to control participants, but no difference in concentra-
tions of IL-1a14, IL-1b14, IL-614, and IL-814. At 1 year following injury,
there was a sustained lower synovial ﬂuid concentration of IL-1ra14
in ACL-D patients when compared to control participants.
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Collagen, Proteoglycan, and Bone Biomarkers (Table VII)<1 week following surgery (four studies)
Within the ﬁrst week following surgery, ACL-R patients pre-
sented with increased synovial ﬂuid concentration of TIMP-126
when compared to baseline concentrations. Plasma concentra-
tions of COMP29 were decreased compared to preoperative con-
centrations during the ﬁrst week following surgery. Also, there
were no changes in synovial ﬂuid concentrations of in MMP-826
and NO33 when compared to preoperative concentrations during
the ﬁrst week following surgery.1 week e 2 months following surgery (two studies)
Between the ﬁrst week and two months following reconstruc-
tive surgery, ACL-R patients presented with greater urinary con-
centrations of CTX-II27 when compared to control participants.
Plasma concentrations of COMP29 were no different than preoper-
ative concentrations by 2 weeks following injury.2 months e 1 year following surgery (two studies)
Between 2 months and 1 year following reconstruction, there
were greater concentrations of urinary CTX-II27 in ACL-R patients
when compared to control participants. However, plasma concen-
trations of COMP29 were not changed from a preoperative con-
centration throughout the 2 month to 1 year time period.>1 year following surgery (three studies)
After the ﬁrst year following surgery, ACL-R patients had greater
concentrations of urinary CTX-II27, serum CS84630, and a larger
ratio of urinary CTX-II to serum CPII31 when compared with control
participants. However, there were decreased concentrations of
serum C12C and C2C when compared to control participants and a
pre-injury concentration30. Therewas heterogeneity in the ﬁndings
for the ratio of C2C to CPII, with no differences between ACL-R and
control participants when the ratio was calculated as urine C2C to
serum CPII31, but lower ratios observed in the ACL-R group when
measuring both biomarker in serum30. For the ratio of C12C to CPII,
the ratios observed in urine to serum of ACL-R patients was greater
than control participants31, but when both biomarkers were
measured in serum the ACL-R patients presented with lower ratios
compared to control participants30 (three studies).
Inﬂammatory Cytokines (Table VII)<1 week following surgery (four studies)
Within the ﬁrst week following surgery, ACL-R patients pre-
sented with increased synovial ﬂuid concentrations of IL-228,
OPN Full32, OPN N-half32, IFN-g28, PDGF28, VEGF28, and BMP-233,
as well as increased plasma concentration of CRP29. Plasma
concentrations of IL-1a29 were unchanged from preoperative
concentrations within the ﬁrst week following injury. However,
there was heterogeneity in biomarker concentration depending
on which sample was used for quantiﬁcation, as evidenced by
increases in synovial ﬂuid concentrations of IL-1b28, IL-628,33,
IL-1ra28, and TGF-b28 compared to a preoperative baseline con-
centration, but no change in plasma concentrations29 when
compared to baseline. Additionally, synovial ﬂuid concentration
of TNF-a28 was decreased from baseline in ACL-R patients, but
there was no change between pre and postoperative concentra-
tions measured in plasma29.1 week e 2 months following surgery (one study)
Between the ﬁrst week and twomonths following surgery, there
was no difference plasma concentrations of IL-1a29, IL-1b29, IL-629,
IL-1ra29, TNF-a29, and CRP29 when compared to pre-operative
concentrations. The only discrepancy within this time period is
that plasma concentrations of TGF-b29 were increased at 2 weeks
following surgery, but by 5 weeks the TGF-b29 concentrations had
returned to being unchanged when compared to preoperative
levels.
2 months e 1 year following surgery (one study)
Between 2 months and 1 year following surgery, there were no
changes between plasma concentrations of IL-1a, IL-1b, IL-6, CRP,
TNF-a, IL-10, IL-1ra, and TGF-b when comparing post-operative to
pre-operative biomarker concentrations.
Discussion
Summary of ACL-D studies
There is evidence from the current literature that ACL-D patients
present with alterations in biomarkers indicative of increased
collagen turnover (Table VI). The integrity of the cartilage extra-
cellular matrix, composed primarily of type II collagen, pro-
teoglycans, and glycosaminoglycans, allows cartilage to resist
repetitive compressive loads34. Breakdown of these structures may
be one of the earliest signs of OA, and is detectable well before
radiographic evidence of the disease35. Indicators of cartilage
breakdown (Tenascin-C15 and COMP23) were increased at an
average of 29 and 103 weeks from injury compared to a control
group. Also, enzymes responsible for degradation of proteoglycans
and collagen (MMP-1, MMP-3) were measured extensively with 16
time points between 3 days and 12 years post injury, with increases
observed in synovial ﬂuid at all time points for MMP-119 and MMP-
317e19,21. TIMP-1, an inhibitor of MMPs, was also observed to be
increased at the same time points as the MMPs17e19,21. However,
the ratio between MMPs and TIMP-1 increased following injury19,
indicating an increase in degradation relative to synthesis. One
study24 reported increased collagen synthesis, due to elevated sy-
novial ﬂuid CPII. Degradation of proteoglycans (aggrecan frag-
ments17,19,21) and glycosaminoglycans (WF6 epitope25) was
observed at time points ranging from an average of two days to
twelve years. One study20 demonstrated that proteoglycan syn-
thesis (aggrecan 846 epitope) is also increased in the synovial ﬂuid
of ACL-D patients. While cartilage breakdown may be one of the
earliest signs of OA, this disease affects all joint structures including
subchondral bone and synovial tissue36. However, bone meta-
bolismwas only investigated in one study22 in ACL-D patients, with
results indicating increased bone degradation due to greater con-
centrations of BSP compared to control participants; and no studies
quantiﬁed synovial tissue metabolism in ACL injured patients.
Collectively, these studies indicate that there are alterations in joint
remodeling as soon as 2 days following injury, with sustained
degradation continuing for at least a decade following injury.
The results regarding the inﬂammatory cytokine response that
occurs in ACL-D patients following injury are inconclusive.
Inﬂammation is required for tissue repair following injury, but the
inﬂux of inﬂammatory cytokines following the initial injury also
mediates the degradation of cartilage, subchondral bone, and sy-
novial tissue indicative of early joint breakdown37 (Table VI). Pro-
inﬂammatory cytokines perpetuate the inﬂammatory process by
down-regulating extracellular synthesis38, increasing chondrocyte
driven extracellular matrix breakdown39, and promoting produc-
tion of MMPs (the enzymes responsible for collagen breakdown)40.
The majority of the pro-inﬂammatory cytokines quantiﬁed in
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concentrations of healthy controls from 1 day to 14 years following
injury (IL-1a14, IL-1b14,16, IL-216, IL-516, IL-1714). However, increases
were observed in TNF-a14,18, IL-614,16,18, and IL-814 at various time
points following initial ACL injury indicating altered inﬂammatory
pathways, which may contribute to the observed collagen degra-
dation. It is important to note that IL-6 and IL-8 are regulatory
proteins that are capable of modulating both pro-inﬂammatory and
anti-inﬂammatory pathways41, but were interpreted as mediators
of inﬂammation by these studies14,16. Anti-inﬂammatory cytokines
act to inhibit the actions of pro-inﬂammatory cytokines; thus,
promoting decreases in degradation and inﬂammation. The anti-
inﬂammatory cytokine response was similar to that of the pro-
inﬂammatory, with the majority of cytokines unchanged
compared to a control group (IL-416, IL-1016, IL-1216, IL-1316). There
were early increases in anti-inﬂammatory IL-1ra14 and IFN-g16,
potentially indicating the body's attempt to counteract the pro-
inﬂammatory response created following joint injury. However,
as time from injury increased, concentrations of IL-1ra were
decreased, which possibly indicates that the body may be less
capable of protecting the cartilage, bone and synovial tissue against
the effectors of degradation for a sustained duration14. Anabolic
cytokines are involved in opposing cartilage degradation by pro-
moting synthesis of components of the cartilage extracellular ma-
trix. The anabolic cytokine response (IL-716, G-CSF16, GM-CSF14,16)
was generally unchanged when compared to synovial ﬂuid con-
centrations of control participants; however, GM-CSF was found to
be increased in patients ranging from 12 weeks to 14 years
following injury14. Overall, the majority of inﬂammatory cytokines
were unchanged in ACL-D patients compared to control partici-
pants; however, increases in TNF-a, IL-6, IL-8, IL-1ra, IFN-g, and
GM-CSF may indicate key inﬂammatory cytokines involved in OA
development following ACL injury.
Summary of ACL-R studies
There were heterogeneous ﬁndings regarding collagen meta-
bolism in studies evaluating ACL-R patients; with serum levels of
collagen metabolism indicating decreased collagen breakdown,
while urine levels indicated an increase (Table VII). Heterogeneous
ﬁndings may be due to different biological ﬂuids (i.e., serum vs
urine) or comparison groups used to quantify cartilage metabolism
(i.e., pre-injury baseline or preoperative concentration). When
collagen metabolism was quantiﬁed by creating a ratio of serum
degradation of CTX-II and C2C to urine synthesis of CPII, there was
increased degradation relative to synthesis at 1 and 3 years
following reconstruction compared to the ratios observed in con-
trol participants31. However, collagen metabolism quantiﬁed by
ratios of serum degradation of C2C and C12C to serum synthesis of
CPII indicated decreased degradation relative to synthesis at 2 years
following initial injury compared to pre-injury ratios in the ACL-R
patients and ratios found in healthy control participants30. Addi-
tionally, collagen degradation measured with urinary CTX-II27 was
increased compared to a control group at all time points (4e16
weeks), but collagen degradation quantiﬁed by serum concentra-
tions of C12C30 and C2C30 was signiﬁcantly decreased compared to
pre-injury concentrations and those of a control group. However, it
is unclear whether the discordance in these collagen biomarkers is
due to the difference in ﬂuid sample (urine vs serum) or reference
group (preoperative vs pre-injury group). Plasma concentrations of
COMP indicate that cartilage degradation was decreased at 3 days,
but unchanged from 2 to 26 weeks when compared to preoperative
concentrations29. Synovial ﬂuid concentrations of the collagen
degradation enzyme (MMP-8) were unchanged at 1 day following
ACL-R when compared to preoperative levels, but increasedconcentrations of an inhibitor of collagen degradation enzymes
(TIMP-1) suggest the body's early attempt at preventing collagen
degradation26. There is evidence that proteoglycan synthesis
(CS846) is increased following reconstruction compared to a con-
trol group, but unchanged when compared to pre-injury baseline
concentrations30.
The overall synovial ﬂuid inﬂammatory cytokine response was
increased following ACL-R compared to preoperative concentra-
tions in the same patients; yet, plasma cytokines demonstrated no
change (Table VII) after ACL-R compared to preoperative concen-
trations. Pro-inﬂammatory cytokine concentrations in synovial
ﬂuid (IL-1b28, IL-228, IL-628,33, OPN32) are all increased within hours
following reconstruction and remain elevated up to a week
following reconstruction. TNF-a was decreased hours following
ACL-R28, but at 1-week post surgery, concentrations were
similar26,33 compared to preoperative baseline concentrations.
Plasma pro-inﬂammatory cytokine concentrations (IL-1a, IL-1b,
CRP, IL-6, TNF-a) were measured in one study29 and were all un-
changed post ACL-R at most time points ranging from 3 days to 26
weeks. Anti-inﬂammatory cytokines followed the same trend, with
synovial ﬂuid concentrations demonstrating increases in IL-1ra28
and IFN-g28, while plasma concentrations of IL-1ra29 and IL-1029
remained unchanged compared to preoperative levels. Addition-
ally, all synovial ﬂuid biomarkers suggesting an anabolic cytokine
response (BMP-233, TGF-B28, VEGF28, PDGF28) were increased
compared to preoperative concentrations, but plasma levels of
TGF-B29 were predominantly unchanged. The results of these
studies28,32,33 provide evidence of an increased inﬂammatory
cytokine response within the ACL-R knee, but utilizing plasma29 for
analysis may not be sensitive enough to determine alterations.
There were no studies that directly evaluated the differences in
biomarker concentrations between ACL-D patients and ACL-R pa-
tients. Therefore, we were unable to conduct an additional com-
parison between ACL-D patients and those that underwent ACL-R.
Future studies should evaluate if remaining ACL-D produces sub-
stantially different biomarker concentrations over a period of years
compared to ACL-R patients. It is critical to know if undergoing
surgical ACL-R changes biomarker concentrations and affects the
eventual risk of OA development; analysis of chronic ACL-D pop-
ulations is often difﬁcult due to the popularity of surgical ACL-R in
treating ACL rupture. However, the pre-operative concentrations in
the longitudinal ACL-R studies can be considered acute ACL-D
concentrations, and the amount of change observed in the post-
operative concentrations indicate how the ACL-R surgery acutely
affects the biomarker concentrations.
Signiﬁcance
OA is very common following ACL injury and reconstruction5;
however, current diagnostic tools indicate presence of the disease
after extensive joint damage has occurred42. Thus, determining
which biomarkers provide the best diagnostic and prognostic
capabilities will allow for early treatment aimed at preventing OA
progression. The current systematic review indicates that synovial
ﬂuid concentrations of cartilage extracellular matrix degradation
(i.e., type II collagen and proteoglycans) are the most consistently
increased OA biomarker following injury and reconstruction.
Currently, the prognostic importance of these alterations in
biomarker concentrations is unclear; some changes may be a
healthy adaptation to injury, while others may be pathologic. Since
the balance of synthesis to degradation is vital for maintaining
overall joint health, an emerging trend in biomarker research is
using turnover ratios (ratio of degradation to synthesis) instead of
individual analysis of either degradation or synthesis30,31.
Following ACL injury and reconstruction, there is an inevitable
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therefore, assessing the turnover ratio will allow for estimation of
overall joint homeostasis. The Osteoarthritis Biomarkers Network
has developed the Burden of Disease, Investigative, Prognostic,
Exploratory, Diagnostic, Safety (BIPEDS) classiﬁcation of bio-
markers that are common to OA biomarker research43. However,
the use of this classiﬁcation system has not translated to the ACL
biomarker literature and the rationale for the use of speciﬁc bio-
markers is often unclear. Due to this, we are unable to determine
the prognostic, diagnostic, or burden of disease utility of these
biomarkers following ACL injury.
Limitations
Due to inconsistent reporting of means and standard deviation
of biomarker concentrations in tabular form within published re-
ports, we were unable to calculate effect sizes to determine the
magnitude of differences between individual biomarkers. A ma-
jority of the studies14,15,19,21e24,27e29,32 presented results in ﬁgures,
while many of the remaining studies that presented results with
tables only provided medians and range17,20,25,30. Additionally, the
heterogeneity within the ACL injured population, lack of reporting
of the concomitant injury characteristics, inconsistent follow-up
times, and lack of longitudinal studies makes it difﬁcult to deﬁni-
tively state that the ACL injury/reconstruction was the sole factor
affecting the alterations in biomarker concentrations.
Implications for future research
Future studies should put the results in context of the BIPEDS
classiﬁcation by incorporating prognostic, diagnostic, and burden
of disease OA biomarkers in patients following a traumatic knee
injury. One challenge associated with this approachmay be the lack
of a deﬁnitive deﬁnition of early OA prior to the presence of
radiographic changes. However, magnetic resonance imaging (MRI)
may be slightly more effective than radiographs at detecting early
cartilage and subchondral bone changes associated with OA44.
Recent MRI advancements, such as T1rho45 and delayed
gadolinium-enhanced MRI of cartilage (dGEMRIC)46, allow for
cartilage evaluation that is sensitive enough to evaluate proteo-
glycan and glycosaminoglycan changes, as well as thickness47, of
the articular cartilage as soon as 1 year post ACL-R. Thus, deter-
mining associations between biomarker concentrations and novel
MRI techniques may aid in classifying biomarkers as either prog-
nostic, diagnostic, or burden of disease during this crucial time
period of early OA. The majority of the included studies only
investigated cartilage biomarkers, with only two studies22,33
investigating bone and none investigating synovial tissue bio-
markers. Since OA is disease of the entire joint, more research is
needed to investigate the entire spectrum of biochemical conse-
quences following ACL injury. The inadequate reporting observed in
the papers included in this review supports the need for stan-
dardization of data presentation in future OA biomarker studies of
ACL-D and ACL-R patients. Basic information that should be
included are: means and standard deviations of biomarker con-
centrations, concomitant injuries (e.g., direct articular cartilage
damage, osteochondral fractures or bone marrow lesions), intra
and inter-assay coefﬁcients of variation. Only three studies27,30,31
included in this review compared ACL-R patients to control par-
ticipants, and no studies conducted longitudinal assessments of
ACL-D patients. Future investigations determining if biomarker
concentration alterations exist between ACL-R, ACL-D, and control
participants would provide critical information about how injury
affects biomarker concentrations and whether surgical recon-
struction modiﬁes the altered biomarker concentrations. With only31% of the total patients being female, the current research under
represents female patients; thus more research is needed to un-
derstand the importance of sex on these biomarkers in this popu-
lation. Many of the studies utilized synovial ﬂuid for biomarker
quantiﬁcation, which allows for injured knee speciﬁc concentra-
tions of biomarkers but may be difﬁcult to collect. Determining
associations between synovial ﬂuid and blood or urine concentra-
tions of similar biomarkers in ACL-D and ACL-R patients would
allow for easier collection of data.
Conclusions
Patients who remain ACL-D have increased biomarker concen-
trations that are indicative of collagen degradation, while current
research does not provide deﬁnitive evidence regarding the in-
ﬂammatory response in ACL-D patients. Following ACL-R, there is
an increased inﬂammatory cytokine response in the synovial ﬂuid
that may contribute to altered tissue turnover in the joint, but
heterogeneous results prevent making conclusions about the effect
of ACL-R on collagen metabolism. Further research with stan-
dardized reporting and utilization of the BIDEPS classiﬁcation is
needed to effectively determine which biomarkers are the most
indicative for OA progression following ACL injury.
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